510(k) K190076
K190076 is an FDA 510(k) premarket notification submitted by Cepheid for the device "Xpert BCR-ABL Ultra, GeneXpert Dx System, GeneXpert Infinity-48s and GeneXpert Infinity-80 Systems". The FDA issued a decision of Substantially Equivalent on September 27, 2019. The device falls under product code OYX (Bcr/Abl1 Monitoring Test), a Class II device regulated under 21 CFR 866.6060. Cepheid has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- September 27, 2019
- Date Received
- January 16, 2019
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Bcr/Abl1 Monitoring Test
- Device Class
- Class II
- Regulation Number
- 866.6060
- Review Panel
- PA
- Submission Type
A BCR/ABL1 Monitoring Test is a quantitative in vitro diagnostic device used to monitor the BCR/ABL1 to ABL1 ratio by reverse-transcriptase quantitative polymerase chain reaction (RQ-PCR) on whole blood or bone marrow of diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) patients expressing BCR-ABL1 fusion transcripts such as e13a2 and/or e14a2. It is intended for use during monitoring of treatment response by reporting results on the international scale (%IS) and as log molecular reduction (MR) value.